AXL as a therapeutic target in STK11 mutant NSCLC

被引：0
|
作者：
Blo, Magnus
Rayford, Austin
Madeleine, Noelly
Gartner, Fabian
Bohan, Dana
Ruggio, Natalie
Li, Huiyu
Girard, Luc
Brekken, Rolf
Minna, John
Anerud, Marianne
Maury, Wendy
Gorcea-Carson, Claudia
Gausdal, Gro
Micklem, David R.
McCracken, Nigel
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3245
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3245
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond
    Amori, Gulanbar
    Sugawara, Emiko
    Inamura, Kentaro
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : E134 - E135
  • [32] Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC
    Kaufman, Jacob
    Owen, Dwight Hall
    Memmott, Regan Michelle
    Otterson, Gregory Alan
    He, Kai
    Presley, Carolyn J.
    Spakowicz, Daniel
    Shields, Peter G.
    Zhang, Xiaoli
    Boyle, Theresa A.
    Cress, W. Douglas
    Wood, Kris
    Ready, Neal E.
    Li, Lang
    Li, Zihai
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Impact of the STK11 mutation on the response to immunotherapy
    Kalantari, A.
    Pieters, T.
    Sawadogo, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S765 - S765
  • [34] STK11 Mutation Identified in Thyroid Carcinoma
    Shuanzeng Wei
    Virginia A. LiVolsi
    Marcia S. Brose
    Kathleen T. Montone
    Jennifer J. D. Morrissette
    Zubair W. Baloch
    Endocrine Pathology, 2016, 27 : 65 - 69
  • [35] STK11 Mutation Identified in Thyroid Carcinoma
    Wei, Shuanzeng
    LiVolsi, Virginia A.
    Brose, Marcia S.
    Montone, Kathleen T.
    Morrissette, Jennifer J. D.
    Baloch, Zubair W.
    ENDOCRINE PATHOLOGY, 2016, 27 (01) : 65 - 69
  • [36] Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers
    Park, Choa
    Lee, Yejin
    Je, Soyeon
    Chang, Shengzhi
    Kim, Nayoung
    Jeong, Euna
    Yoon, Sukjoon
    MOLECULES AND CELLS, 2019, 42 (11) : 804 - 809
  • [37] Serine/threonine kinase 11 (STK11) associated adnexal tumors: from biology to therapeutic impact
    Huang, Guanxiang
    Lin, Wenyu
    Jiang, Tingting
    Cai, Yuanjun
    Lin, Chengbin
    Sun, Pengming
    HUMAN GENOMICS, 2025, 19 (01)
  • [38] Clinical Outcomes for Patients With Stage III NSCLC and STK11 or KEAP1 Genetic Alterations
    Taasan, S.
    Wolf, S.
    Wang, X.
    Antonia, S.
    Crawford, J.
    Ready, N.
    Stinchcombe, T.
    Clarke, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1042 - S1042
  • [39] Metabolic profile and therapeutic vulnerabilities of multi-omic characterization ofKRAS/STK11/KEAP1 co-mutant non-small cell lung cancer (NSCLC).
    Sen, Triparna
    Sen, Utsav
    Coleman, Charles
    Elliott, Andrew
    Hasson, Dan
    Vanderwalde, Ari M.
    Ma, Patrick C.
    Gandhi, Nishant
    Halmos, Balazs
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Metformin promotes anti-tumor immunity in STK11 mutant NSCLC through AXIN1-dependent upregulation of multiple nucleotide metabolites
    Wang, Zhiguo
    Li, Kunlin
    Lu, Conghua
    Feng, Mingxia
    Lin, Caiyu
    Yin, Guofang
    Luo, Dan
    Liu, Wenyi
    Jin, Kaiyu
    Dou, Yuanyao
    Wu, Di
    Zheng, Jie
    Zhang, Kejun
    Li, Li
    Fan, Xianming
    ONCOLOGY RESEARCH, 2024, 32 (10) : 1637 - 1648
12345